CN102036672A - 呈现血管发生抑制作用的抗肿瘤类萜烯药物组合物abisilin - Google Patents

呈现血管发生抑制作用的抗肿瘤类萜烯药物组合物abisilin Download PDF

Info

Publication number
CN102036672A
CN102036672A CN2008801288610A CN200880128861A CN102036672A CN 102036672 A CN102036672 A CN 102036672A CN 2008801288610 A CN2008801288610 A CN 2008801288610A CN 200880128861 A CN200880128861 A CN 200880128861A CN 102036672 A CN102036672 A CN 102036672A
Authority
CN
China
Prior art keywords
abisilin
tumor
medicine
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801288610A
Other languages
English (en)
Chinese (zh)
Inventor
N·M·皮尼吉娜
L·A·莱特瑟鲁斯
A·U·巴利辛尼科夫
F·I·马加诺娃
A·M·科兹洛夫
Z·S·斯米尔诺夫娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "INITIUM-PHARM"
Original Assignee
OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "INITIUM-PHARM"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "INITIUM-PHARM" filed Critical OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "INITIUM-PHARM"
Publication of CN102036672A publication Critical patent/CN102036672A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801288610A 2008-03-14 2008-03-14 呈现血管发生抑制作用的抗肿瘤类萜烯药物组合物abisilin Pending CN102036672A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2008/000147 WO2009113902A1 (ru) 2008-03-14 2008-03-14 Пpoтивooпyxoлeвaя терпеноидная фармацевтическая композиция «aбиcилин» с ангиогенезингибирующим дeйcтвиeм

Publications (1)

Publication Number Publication Date
CN102036672A true CN102036672A (zh) 2011-04-27

Family

ID=41065440

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801288610A Pending CN102036672A (zh) 2008-03-14 2008-03-14 呈现血管发生抑制作用的抗肿瘤类萜烯药物组合物abisilin

Country Status (9)

Country Link
US (1) US20110165271A1 (https=)
EP (1) EP2275112A4 (https=)
JP (1) JP2011514354A (https=)
KR (1) KR20110015516A (https=)
CN (1) CN102036672A (https=)
CA (1) CA2727792C (https=)
EA (1) EA017659B1 (https=)
IL (1) IL208092A (https=)
WO (1) WO2009113902A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102657660A (zh) * 2012-04-28 2012-09-12 上海交通大学医学院 三萜类化合物在制备抑制血管生成药物中的应用
CN116710113A (zh) * 2020-09-30 2023-09-05 伊尼蒂雅姆-医药有限责任公司 用于刺激自噬的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013176564A1 (ru) * 2012-05-25 2013-11-28 Общество С Ограниченной Ответственностью "Инитиум-Фарм" Терпеноидное средство для профилактики и лечения атеросклероза и коррекции метаболического синдрома
RU2634253C1 (ru) * 2016-12-22 2017-10-24 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Антиангиогенное лекарственное средство
RU2747147C1 (ru) * 2020-06-22 2021-04-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Фармацевтическая композиция, проявляющая цитотоксичность в отношении клеток карциномы толстой кишки человека

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051900C1 (ru) 1991-02-15 1996-01-10 Санкио Компани Лимитед 5-амино-1-гидроксиметилциклопентан-1,2,3,4-тетраол, 2-амино-4-гидроксиметил-3a,5,6,6a-тетрагидро-4н-циклопент-[d]-оксазол-4,5,6-триол, их фармацевтически приемлемые соли и способы их получения
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5488116A (en) * 1992-03-30 1996-01-30 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol and analogues thereof
RU2054945C1 (ru) 1995-06-28 1996-02-27 Нина Максимовна Пинигина Средство "абисил-1", обладающее противовоспалительной, антибактериальной и ранозаживляющей активностью
RU2196581C2 (ru) 2000-05-04 2003-01-20 Колесников Андрей Григорьевич Способ получения r-тетраола, обладающего противоопухолевой активностью
NZ536196A (en) 2000-06-23 2006-12-22 Schering Ag Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
RU2198653C1 (ru) * 2002-03-29 2003-02-20 Пинигина Нина Максимовна Полиактивные ректальные или вагинальные суппозитории на основе природных терпенов, обогащенных монотерпеноидами, для лечения и/или профилактики урологических, проктологических или гинекологических заболеваний
AU2003264192A1 (en) * 2002-08-30 2004-03-19 Biopharmacopae Design International Inc. Plant extracts for treatment of angiogenesis and metastasis
RU2244928C2 (ru) 2003-02-19 2005-01-20 Пинигина Нина Максимовна Эндогенная фармацевтическая композиция, полученная на основе целенаправленной активации гуморальных медиаторов нервных окончаний коры головного мозга
RU2338547C1 (ru) * 2007-02-16 2008-11-20 Людмила Анатольевна Лацерус Полиактивная терпеноидная субстанция абисил-2, фармацевтическая композиция на ее основе и способы ее применения

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102657660A (zh) * 2012-04-28 2012-09-12 上海交通大学医学院 三萜类化合物在制备抑制血管生成药物中的应用
CN116710113A (zh) * 2020-09-30 2023-09-05 伊尼蒂雅姆-医药有限责任公司 用于刺激自噬的方法

Also Published As

Publication number Publication date
IL208092A (en) 2015-07-30
IL208092A0 (en) 2010-12-30
JP2011514354A (ja) 2011-05-06
US20110165271A1 (en) 2011-07-07
CA2727792C (en) 2017-07-25
WO2009113902A1 (ru) 2009-09-17
CA2727792A1 (en) 2009-09-17
EA017659B1 (ru) 2013-02-28
EP2275112A4 (en) 2011-10-12
EP2275112A1 (en) 2011-01-19
KR20110015516A (ko) 2011-02-16
EA201001289A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
US8247435B2 (en) Formulations for treating human and animal diseases
US20110293753A1 (en) Tocotrienol Compositions
Anadón et al. Interactions between nutraceuticals/nutrients and therapeutic drugs
JP2018534254A5 (https=)
WO2001078783A2 (en) Compositions comprising natural agents for treatment of cancer
CN102036672A (zh) 呈现血管发生抑制作用的抗肿瘤类萜烯药物组合物abisilin
EP1667528A1 (en) Hippophae rhamnoides compositions for cancer therapy
JP4944380B2 (ja) 抗腫瘍活性および抗毒活性のある抽出物
AU2002246080B2 (en) Method for Cancer Therapy
JPH08503451A (ja) 癌治療のモダリティーとしての３‐ヒドロキシ‐３‐メチルグルタリルＣｏＡレダクターゼ阻害剤の使用
Uzun et al. Sesquiterpenes and prostate cancer
KR20060032996A (ko) 전립선 장애의 치료와 예방을 위한 식물성 조성물
CN107260734B (zh) 一种具有抗肺癌作用的复方药物组合物及其用途
US20110117070A1 (en) Compositions and methods for treating headache
Aljeboory et al. Loranthus Europaeus is an alternative medicine in treatment of cyst and mouth inflammation resulted from chemotherapy of breast cancer
EP2485746A2 (en) Cytoprotective or therapeutic plant composition
CN101953839B (zh) 一种具有抗急性髓性白血病作用的复方药物组合物
Li et al. Advances of plant-derived natural products in ovarian cancer therapy
JP2016530326A (ja) ロクベンシモツケソウ抽出物及びその用途
Papakotsi et al. Alaska’s Flora as a Treatment for Cancer
JP2014224148A (ja) 血管新生阻害作用を示す抗腫瘍テルペノイド医薬組成物アビシリン
JP7825729B2 (ja) 前立腺の健康及び前立腺癌予防のためのハーブ組成物
JP2005501128A (ja) ガンの治療における抗腫瘍剤の増強物質
CA2276276A1 (en) Cancer treatment drug
RU2310343C1 (ru) Биологически активная добавка для профилактики заболеваний мужской мочеполовой сферы

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110427